
Arcellx (ACLX) Stock Forecast & Price Target
Arcellx (ACLX) Analyst Ratings
Bulls say
Arcellx Inc. exhibits a robust commercial advantage through its collaboration with Gilead, which provides access to advanced CAR-T cell therapy manufacturing and patient support, thereby enhancing its market position in the oncology sector. The promising clinical profile of Arcellx’s Anito-cel therapy for multiple myeloma, showing durability comparable to established CAR-T treatments, supports a significant potential sales estimate of $7 billion as broader label expansions may follow. The strategic partnership with Kite positions the company favorably for profitability as Arcellx approaches anticipated regulatory approval and a successful market entry, further validating its growth trajectory and shareholder value creation.
Bears say
Arcellx Inc. faces significant risks that contribute to a negative outlook for its stock, primarily stemming from uncertainties surrounding its clinical programs and the recent acquisition proposal from Gilead Sciences, valued at $7.8 billion. The company may struggle to produce additional successful therapies from its D-Domain CAR-T and ARC-SparX platforms, leading to potential commercial challenges, heightened competition, and insurance pricing pressures. Furthermore, the complexity of the acquisition, along with clinical, regulatory, and financing risks, raises concerns about the stability and future value of Arcellx's stock.
This aggregate rating is based on analysts' research of Arcellx and is not a guaranteed prediction by Public.com or investment advice.
Arcellx (ACLX) Analyst Forecast & Price Prediction
Start investing in Arcellx (ACLX)
Order type
Buy in
Order amount
Est. shares
0 shares